TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05143073

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol use disorder and strategies to reduce risk educational material
Description: Participants will be directed to educational information (\~5 minutes) regarding alcohol use disorder and strategies to reduce risk which they will read.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Complex polygenic risk scores, alcohol use disorder, and strategies to reduce risk educational material
Description: Participants will be directed to educational information (\~10 minutes) regarding complex polygenic risk scores, alcohol use disorder and strategies to reduce risk which they will read.
Study: NCT05692037

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres
Description: Yttrium-90 carbon microspheres SIRT
Study: NCT05393466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-361175
Description: BPI-361175 is an oral fourth-generation EGFR inhibitor. The activation of EGFR signaling pathways is associated with various biological events such as proliferation, migration, differentiation, and apoptosis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-361175
Description: BPI-361175 is an oral fourth-generation EGFR inhibitor. The activation of EGFR signaling pathways is associated with various biological events such as proliferation, migration, differentiation, and apoptosis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-361175
Description: BPI-361175 is an oral fourth-generation EGFR inhibitor. The activation of EGFR signaling pathways is associated with various biological events such as proliferation, migration, differentiation, and apoptosis.
Study: NCT05472727

Intervention type: OTHER
Intervention: reaction time test
Description: Reaction time tests consist of 3 sub-parameters as simple reaction time, selective reaction time and distinctive reaction time. Participants will do these tests on the computer.

Intervention type: OTHER
Intervention: reaction time test
Description: Reaction time tests consist of 3 sub-parameters as simple reaction time, selective reaction time and distinctive reaction time. Participants will do these tests on the computer.

Intervention type: OTHER
Intervention: Physical fitness test
Description: The physical fitness test will be evaluated with the senior fitness test used for geriatrics and the 8 meter walking speed test.

Intervention type: OTHER
Intervention: Physical fitness test
Description: The physical fitness test will be evaluated with the senior fitness test used for geriatrics and the 8 meter walking speed test.
Study: NCT05688943

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia
Description: Fentanyl (1µg/kg) and midazolam are administered intravenously prior to puncture. Using an aseptic technique, the subarachnoid space is punctured with a 25/27 gauge needle in the intervertebral space, and a standard dose of chloroprocaine 45-60mg is injected. Alternative spinal anesthetics include bupivacaine 6-15mg and mepivacaine 50-70mg. The participant is then placed in the supine position in 10-degree Trendelenburg until the lack of sensitivity is adequate at spinal level T4.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: General anesthesia is a state of controlled unconsciousness. During a general anesthetic, medicines are used to send the participant to sleep making the participant unaware of surgery and so that the participant does not move or feel pain while the surgery is carried out. Induction of general anesthesia includes the use intravenous sedative-hypnotic agents such as propofol, etomidate, or ketamine, along with adjuvant agents such as fentanyl, lidocaine, or midazolam. A neuromuscular blocking agent such as succinylcholine or rocuronium is used to facilitate endotracheal intubation.
Study: NCT06771128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo Biloba oral tablet
Description: patients receive Ginkgo Biloba oral tablet 120 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin Acetate 0.2 mg Tablets
Description: patient receives desmopressin 0.2 mg oral tablet once daily
Study: NCT05797701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443820
Description: Tablet by oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443820
Description: Tablet by oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443820
Description: Tablet by oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443820
Description: Capsule by oral administration
Study: NCT05167942

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: deep transcranial magnetic stimulation with H1 coil
Description: Sham deep transcranial magnetic stimulation on PFC .Duration:40 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency deep transcranial magnetic stimulation with H1 coil
Description: high frequency(20Hz) deep transcranial magnetic stimulation on PFC .Duration:40 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS deep transcranial magnetic stimulation with H1 coil
Description: iTBS deep transcranial magnetic stimulation on PFC .Duration:40 days.
Study: NCT04879043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDP-101
Description: HDP-101 is available as lyophilized white powder for preparation of infusion.
Study: NCT06260254

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Railway noise
Description: Low level railway noise, not exceeding 50 dB LAF,max. Thirty six single railway noise events.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Railway noise
Description: Low level railway noise, not exceeding 50 dB LAF,max. Thirty six single railway noise events.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Railway noise
Description: Low level railway noise, not exceeding 50 dB LAF,max. Thirty six single railway noise events.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low level railway vibration
Description: 36 single railway noise events at 0.5 mm/s, varying from 11.5 s to 56.9 s in duration. Vibration always occurs concurrently with the noise exposure.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intermediate level railway vibration
Description: 36 single railway noise events at 0.7 mm/s, varying from 11.5 s to 56.9 s in duration. Vibration always occurs concurrently with the noise exposure.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High level railway vibration
Description: 36 single railway noise events at 0.9 mm/s, varying from 11.5 s to 56.9 s in duration. Vibration always occurs concurrently with the noise exposure.
Study: NCT05446545

Intervention type: OTHER
Intervention: ND-EOC or platinum-sensitive rEOC
Description: platinum-based combined chemotherapy or bevacizumab will be used for adjuvant treatment, followed by maintenance therapy with poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, or bevacizumab, or other anti-tumor angiogenesis drugs or immune checkpoint inhibitors
Study: NCT05680363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HyperSperm
Description: Multi-step sperm preparation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Sperm Preparation
Description: Standard sperm preparation
Study: NCT05479500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Chain Release Techniques
Description: Myofascial release is a hands on technique which stretches the fascia and releases, bonds between muscles, integuments and fascia in order to eliminate pain, improve motion and to maintain myofascial balance within the body.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Release Techniques
Description: Local Release Techniques are a soft tissue method that focuses on relieving tissue tension via the removal of fibrosis/adhesions which can develop in tissues as a result of overload due to repetitive use.
Study: NCT06374823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Electrolyte
Description: Patients who are randomized to multiple electrolyte group will be receiving Multiple Electrolytes injection II for 72 hours continously after inrollment as maintence and rescutation fluids. Infusion speed and volume will be determained by physicians.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Patients who are randomized to normal saline group will be receiving Sodium Chloride injection for 72 hours continously after inrollment as maintence and rescutation fluids. Infusion speed and volume will be determained by physicians.
Study: NCT05235035

Intervention type: BEHAVIORAL
Intervention: Night shift work
Description: Subjects are exposed to irregular sleep and sleep misalignment due to hospital night shifts.
Study: NCT06771128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin Acetate 0.2 mg Tablets
Description: patient receives desmopressin 0.2 mg oral tablet once daily
Study: NCT04943497

Intervention type: OTHER
Intervention: ribociclib
Description: There is no treatment allocation. Patients administered ribociclib by prescription that have started before inclusion of the patient into the study will be enrolled.

Intervention type: OTHER
Intervention: aplelicib
Description: There is no treatment allocation. Patients administered aplelicib by prescription that have started before inclusion of the patient into the study will be enrolled.

Intervention type: OTHER
Intervention: mono endocrine therapy
Description: There is no treatment allocation. Patients administered mono endocrine therapy by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT06518122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306
Description: Take it once a day per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306
Description: Take it once a day per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306
Description: Take it once a day per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306
Description: Take it once a day per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306
Description: Take it once a day per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306
Description: Take it once a day per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306
Description: Take it once a day per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2302
Description: Take it once a day per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2302
Description: Take it once a day per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2302
Description: Take it once a day per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2302
Description: Take it once a day per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2302
Description: Take it once a day per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2302
Description: Take it once a day per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2302
Description: Take it once a day per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2102
Description: Take it once a day per period
Study: NCT04887493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprostol 25µg will be used for both the study arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprostol 25µg will be used for both the study arms
Study: NCT06290050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam syrup.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam syrup.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Repaglinide tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Repaglinide tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsules.
Study: NCT04943497

Intervention type: OTHER
Intervention: chemotherapy
Description: There is no treatment allocation. Patients administered chemotherapy by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT06136546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Intravenous infusion of infliximab

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of saline solution (matching in color and consistency in infliximab)
Study: NCT06037330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: Nalbuphine was injected intravenously. The target CPOT score was \<2, and the target RASS score was -2 \~ 1. 40 mg of nalbuphine was diluted into 50 mL solution, the load was 0.1mg/kg, the maintenance dose was 0.04-0.08mg/kg/h, the CPOT score was \<2, and the maximum daily dose was 160mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Sufentanil was injected intravenously, and the target CPOT score was \<2, and the target RASS score was -2 \~ 1. 0.1mg of sufentanil was diluted into 50 mL solution, the loading dose was 0.2-0.5μg/kg, the maintenance dose was 0.2-0.3μg/kg/h, and the CPOT score was \<2 points
Study: NCT06087354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The way of Cumulus-oocyte complexes (COC) CAPA-IVM culture condition
Description: Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM 24 hrs capacitation followed by 30h maturation. The first group will be cultured in low oxygen concentration (5%Oxygen), 6% carbon dioxide at 37 degree. The second group will be cultured in air oxygen concentration (20%Oxygen), 6% carbon dioxide at 37 degree.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The way of Cumulus-oocyte complexes (COC) CAPA-IVM culture condition
Description: Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM 24 hrs capacitation followed by 30h maturation. The first group will be cultured in low oxygen concentration (5%Oxygen), 6% carbon dioxide at 37 degree. The second group will be cultured in air oxygen concentration (20%Oxygen), 6% carbon dioxide at 37 degree.
Study: NCT04495309

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Metastases-directed Radiotherapy
Description: Ablative radiotherapy (radiosurgery, stereotactic radiotherapy, hypofractionated image-guided radiotherapy (IGRT)) with few high-dose fractions
Study: NCT04791046

Intervention type: DRUG
Intervention: antihypertensive therapy
Description: Personalized evidence-based antihypertensive therapy in patients with comorbidities

Intervention type: DRUG
Intervention: antihypertensive therapy
Description: Personalized evidence-based antihypertensive therapy in patients with comorbidities
Study: NCT06240884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infraspinatus-teres minor interfascial block
Description: After identifying the infraspinatus and teres minor muscles on the posterior surface of the scapular neck. Under real-time ultrasound guidance, the needle is advanced into the interfascial plane between the infraspinatus and teres minor muscles using an in-plane technique, and after confirming the fascial opening with 3 to 5 mL of 0.375% ropivacaine (20 mL total dose), the remaining 0.375% ropivacaine is injected. After extubation and the patients were awake, anesthesiologists who were unaware of the study subgroups began to assess the analgesic effect of the patients' block at rest using the numeric pain rating scale (NRS) at 0.5h, 3h, 6h, 12h, 18h, 24h, and 48h postoperatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interscalene block
Description: The tip of the needle was placed between the C5 and C6 nerve roots, and after a bloodless retraction with 0.5 to 1 ml of 0.375% ropivacaine to confirm nerve displacement, the remaining 0.375% ropivacaine was injected (total dose of 20 ml). Subsequently, the catheter was inserted over the needle and the needle was withdrawn.After extubation and the patients were awake, anesthesiologists who were unaware of the study subgroups began to assess the analgesic effect of the patients' block at rest using the numeric pain rating scale (NRS) at 0.5h, 3h, 6h, 12h, 18h, 24h, and 48h postoperatively.
Study: NCT06329037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Administration of Vasopressin (20 IU) (oral spray)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of Placebo (oral spray)
Study: NCT05567237

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microcurrent treatment with resistance exercise programme
Description: This intervention will allow us to explore the effects of microcurrent added to resistance exercise.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Resistance exercise programme
Description: This intervention works as a control group for the participants undergoing the exercise programme.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microcurrent treatment
Description: This intervention will allow us to explore the effects of microcurrent alone.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No treatment
Description: This intervention works as a control group for the participants who are not taking part into the exercise programme.
Study: NCT04943991

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sampling (alpha-Galactosidase & LysoGb3)
Description: A blood sample will be taken. Alpha-Galactosidase level and LysoGb3 will be measured.~Amendment: Offering of genetic testing for fabry specific GLA-gene
Study: NCT05138835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox Cosmetic
Description: BOTOX® Cosmetic is approved and commercially available for use in Canada.~BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe frown lines between the eyebrows, crow's feet lines, and forehead lines in adults.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox Cosmetic
Description: BOTOX® Cosmetic is approved and commercially available for use in Canada.~BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe frown lines between the eyebrows, crow's feet lines, and forehead lines in adults.
Study: NCT05852756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pecha kucha
Description: pecha kucha training
Study: NCT06569992

Intervention type: OTHER
Intervention: VIS, TIES
Description: The vasopressor and inotropic drug dosages administered during the follow-up of these patients will be recorded, and the Vasoactive-Inotropic Score (VIS) and Total Inotrope Exposure Score (TIES) will be calculated.

Intervention type: OTHER
Intervention: VIS, TIES
Description: The vasopressor and inotropic drug dosages administered during the follow-up of these patients will be recorded, and the Vasoactive-Inotropic Score (VIS) and Total Inotrope Exposure Score (TIES) will be calculated.
Study: NCT05832281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Purysis CBD
Description: Participants will receive Purysis, or synthetic CBD, which will be compared to placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Purysis
Study: NCT06092073

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: recto-intercostal fascial plane block
Description: Patients will receive bilateral recto-intercostal fascial plane block using 20 mL of bupivacaine 0.25% on each side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Description: bupivacaine 0.25%
Study: NCT05583266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline sustained-release tablets
Description: a dose of 1 tablet twice a day of Pentoxifylline sustained-release tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pentoxifylline sustained-release tablets placebo
Description: Pentoxifylline sustained-release tablets placebo will be administrated at the same dosage and frequency as the experimental group
Study: NCT05912842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organizational Partnerships for Healthy Living
Description: Component 1 is a comprehensive training for all MLP care providers delivered to clinical, social and behavioral, and legal staff together to establish a collaborative environment. Component 2 consists of the screening tool and screening protocol that is designed to identify health-harming legal needs of PLWH patients. Component 3 includes the provision of legal support through partnership with the Legal Clinic for the Disabled.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Comparison arm health organization will only receive the HIV standard of care (U.S. CDC HIV standard of care) and referral to legal aid.
Study: NCT05149690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: monopolar dielectric diathermy and supervised therapeutic exercise
Description: The Experimental Group formed by 30 subjects will undergo an application of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device developed by the electro-medicine company Biotronic Advance Develops SL, on the lumbar musculature by means of rotary movements and translation, adapting to the muscle fibers of the lumbar area. A pulsed emission of 840 KHz and 30v will be made dynamically during a treatment time of 20 minutes. Once the application of (MDR) is finished, an exercise program supervised by a physiotherapist will be carried out. The exercise program will consist mainly of three types: stability and lumbo-pelvic motor control, strengthening and stretching of the lumbar muscles (Annex XIV), with a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday, a total of 8 treatment sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Supervised therapeutic exercise
Description: The Control Group formed by 30 subjects will be administered a training program consisting of three types of exercises, taking into account: stability and lumbopelvic motor control, strengthening and stretching of the lumbar muscles, exactly the same as the Experimental Group. With a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday with a total of 8 treatment sessions.
Study: NCT06130267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endocare
Description: Virtual paradigm (calming environnement)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Endocare
Description: Virtual paradigm (calming environnement)